How I treat How I treat patients who mobilize hematopoietic stem cells poorly
نویسندگان
چکیده
1Haematology, Institute of Medical and Veterinary Science/SA Pathology and Royal Adelaide Hospital, Adelaide, Australia; 2School of Medicine, University of Adelaide, Adelaide, Australia; 3Mater Medical Research Institute, South Brisbane, Australia; 4School of Medicine, University of Queensland, Brisbane, Australia; and 5Division of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia
منابع مشابه
How I treat patients who mobilize hematopoietic stem cells poorly.
Transplantation with 2-5 × 10(6) mobilized CD34(+)cells/kg body weight lowers transplantation costs and mortality. Mobilization is most commonly performed with recombinant human G-CSF with or without chemotherapy, but a proportion of patients/donors fail to mobilize sufficient cells. BM disease, prior treatment, and age are factors influencing mobilization, but genetics also contributes. Mobili...
متن کاملHow I treat bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation.
In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly universal mortality secondary to lack of consensus for diagnostic criteria, poorly understood disease pathogenesis, and very few studies of therapeutic or supportive care interventions. Recently, however, progress has been made in these areas: revised conse...
متن کاملHow I treat How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation
Hepatitis B virus (HBV) reactivation is a serious but preventable complication of immunosuppression. Full HBV serologic profile must be obtained from all patients receiving intensive immunosuppressive therapy. In general, preemptive anti-HBV therapy is more effective than giving treatment after development of reactivation. Prompt lamivudine therapy should be given to at-risk patients who are he...
متن کاملHow I treat How I treat relapsed childhood acute lymphoblastic leukemia
The most common cause of treatment failure in childhood acute lymphoblastic leukemia (ALL) remains relapse, occurring in 15%-20% of patients. Survival of relapsed patients can be predicted by site of relapse, length of first complete remission, and immunophenotype of relapsed ALL. BM and early relapse (< 30 months from diagnosis), as well as T-ALL, are associated with worse prognosis than isola...
متن کاملHow I treat How I treat myelofibrosis
It is currently assumed that myelofibrosis (MF) originates from acquired mutations that target the hematopoietic stem cell and induce dysregulation of kinase signaling, clonal myeloproliferation, and abnormal cytokine expression. These pathogenetic processes are interdependent and also individually contributory to disease phenotype–bone marrow stromal changes, extramedullary hematopoiesis, inef...
متن کامل